NLGN3 (Neuroligin-3) variants and mutations
NLGN3 (also known as Neuroligin-3) is a human protein-coding gene encoding a neuroligin-3 protein. It organizes postsynaptic adhesion and helps align synaptic signaling machinery with presynaptic release sites. Rare pathogenic variants can cause neurodevelopmental disorders with autism-related features and intellectual disability, although phenotype and penetrance vary. This analysis covers 749 NLGN3 variants and mutations. Of these, 69% have computational variant effect predictions. Disease context includes autism spectrum disorder, autism, and hereditary disease. Example NLGN3 variants include M1R, W2C, and L3L.
Variant analysis overview
- Gene: NLGN3
- Protein: Neuroligin-3
- UniProt accession: Q9NZ94
- Organism: Homo sapiens
- Variants analyzed: 749
- Variant scope: all variants
- Completed: 2026-08-19
Variant and mutation evidence
- Variant composition: 538 unspecified-consequence records; 87 missense variants; 101 synonymous variants; 2 in-frame insertions; 9 stop-gained variants; 7 frameshift variants; 2 splice-region variants; 3 substitution
- Prediction scores: 516 variants have prediction scores (69% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: autism spectrum disorder, autism, hereditary disease, Intellectual disability, neurodegenerative disease, X-linked complex neurodevelopmental disorder, hypogonadotropic hypogonadism, Autistic behavior, central nervous system cancer, glioma, glioblastoma, genetic developmental and epileptic encephalopathy.
Protein structure and variant hotspots
- Protein features: 1 transmembrane segments; 4 post-translational modification sites.
- Structural context: 14 variants have structural context.
- PTM context: 2 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, ClinGen, MaveDB, LitVar.
Notable NLGN3 variants
Examples include M1R, W2C, L3L, R4Q, R4W, R4R, L5I, L5R. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- M1R (p.Met1Arg), rs2519734418, ClinGen CA413546466, ClinVar RCV003109941, Uncertain significance, not provided
- W2C (p.Trp2Cys), gnomAD X-71147755-G-T, REVEL 0.35, CADD 27.20
- L3L (p.Leu3Leu), gnomAD X-71147756-C-T, CADD 9.80
- R4Q (p.Arg4Gln), ExAC rs777428627, gnomAD rs777428627, REVEL 0.12, CADD 13.90
- R4W (p.Arg4Trp), rs376877146, ClinGen CA10444960, ClinVar RCV000487940, ClinVar RCV001821407, REVEL 0.19, CADD 22.00, Benign
- R4R (p.Arg4Arg), rs376877146, gnomAD X-71147759-C-A, CADD 8.73
- L5I (p.Leu5Ile), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- L5R (p.Leu5Arg), NCI-TCGA TCGA novel, REVEL 0.31, CADD 23.00, Variant assessed as somatic; moderate impact.
- L5F (p.Leu5Phe), gnomAD X-71147762-C-T, REVEL 0.10, CADD 17.60
- G6D (p.Gly6Asp), NCI-TCGA Cosmic COSV1007, cosmic curated COSV10070, NCI-TCGA Cosmic COSV6244, Variant assessed as somatic; moderate impact.
- G6V (p.Gly6Val), NCI-TCGA Cosmic COSV1007, NCI-TCGA Cosmic COSV6244, cosmic curated COSV62444, Variant assessed as somatic; moderate impact.
- G6C (p.Gly6Cys), gnomAD X-71147765-G-T, REVEL 0.23, CADD 19.40
- G6G (p.Gly6Gly), gnomAD X-71147767-C-T, CADD 9.12
- P7L (p.Pro7Leu), rs199925687, ClinGen CA241764, ClinVar RCV000175914, 1000Genomes rs199925687, REVEL 0.07, CADD 1.35, Uncertain significance
- P7S (p.Pro7Ser), TOPMed rs1482387660
- P7Q (p.Pro7Gln), gnomAD X-71147769-C-A, REVEL 0.07, CADD 0.59
- P7P (p.Pro7Pro), gnomAD X-71147770-G-T, CADD 4.47
- P8L (p.Pro8Leu), TOPMed rs2092375976, REVEL 0.09, CADD 18.30
- S9L (p.Ser9Leu), rs777601149, ClinGen CA330989496, ClinVar RCV001193947, 1000Genomes rs777601149, REVEL 0.06, CADD 12.50, Uncertain significance, not specified
- S9P (p.Ser9Pro), Ensembl rs941859085
- S9S (p.Ser9Ser), rs781426057, gnomAD X-71147776-G-A, CADD 8.43
- L12P (p.Leu12Pro), TOPMed rs2092376044
- L12V (p.Leu12Val), gnomAD X-71147783-C-G, REVEL 0.05, CADD 9.72
- L12R (p.Leu12Arg), gnomAD X-71147784-T-G, REVEL 0.33, CADD 15.10
- S13N (p.Ser13Asn), rs2092376058, ClinGen CA413546659, ClinVar RCV001175512, Ensembl rs2092376058, REVEL 0.10, CADD 9.37, Uncertain significance, not specified
- P14L (p.Pro14Leu), gnomAD X-71147790-C-T, REVEL 0.07, CADD 16.10
- K15R (p.Lys15Arg), TOPMed rs2092376075
- K15N (p.Lys15Asn), gnomAD X-71147794-G-T, REVEL 0.04, CADD 6.09
- P16H (p.Pro16His), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- P16S (p.Pro16Ser), gnomAD X-71147795-C-T, REVEL 0.03, CADD 8.36
- P16P (p.Pro16Pro), rs745903511, gnomAD X-71147797-C-T, CADD 6.43
- T17K (p.Thr17Lys), ExAC rs769930005, TOPMed rs769930005, gnomAD rs769930005, REVEL 0.11, CADD 10.40
- T17M (p.Thr17Met), cosmic curated COSV62442, ExAC rs769930005, TOPMed rs769930005, gnomAD rs769930005, REVEL 0.08, CADD 11.40
- T17R (p.Thr17Arg), ExAC rs769930005, TOPMed rs769930005, gnomAD rs769930005, REVEL 0.27, CADD 9.41
- T17A (p.Thr17Ala), gnomAD X-71147798-A-G, REVEL 0.03, CADD 4.77
- T17T (p.Thr17Thr), gnomAD X-71147800-G-T, CADD 0.28
- V18A (p.Val18Ala), TOPMed rs1193269621, gnomAD rs1193269621, REVEL 0.15, CADD 12.30
- V18F (p.Val18Phe), gnomAD X-71147801-G-T, REVEL 0.26, CADD 10.70
- G19S (p.Gly19Ser), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- G19G (p.Gly19Gly), gnomAD X-71147806-C-A, CADD 6.11
- R20R (p.Arg20Arg), gnomAD X-71147809-G-A, CADD 7.68
- S21R (p.Ser21Arg), ESP rs139781549, ExAC rs139781549, TOPMed rs139781549, gnomAD rs139781549, REVEL 0.32, CADD 12.50
- S21T (p.Ser21Thr), gnomAD X-71147811-G-C, REVEL 0.13, CADD 14.10
- L22V (p.Leu22Val), Ensembl rs2092376202, REVEL 0.18, CADD 15.60
- L22L (p.Leu22Leu), rs1278488102, gnomAD X-71147815-G-A, CADD 7.66
- L24F (p.Leu24Phe), cosmic curated COSV10889, 1000Genomes rs754055025, ExAC rs754055025, TOPMed rs754055025, REVEL 0.16, CADD 15.30, Uncertain significance, Inborn genetic diseases
- L24H (p.Leu24His), NCI-TCGA Cosmic COSV6244, cosmic curated COSV62442, Variant assessed as somatic; moderate impact.
- p.Leu24 Thr25insIle, rs1569483552, gnomAD X-71147819-C-CTCA, CADD 15.40
- T25N (p.Thr25Asn), gnomAD rs1276384512, REVEL 0.07, CADD 9.35
- T25A (p.Thr25Ala), gnomAD X-71147822-A-G, REVEL 0.14, CADD 12.10
- T25I (p.Thr25Ile), gnomAD X-71147823-C-T, REVEL 0.12, CADD 10.00
- T25T (p.Thr25Thr), gnomAD X-71147824-C-T, CADD 6.54
- L26V (p.Leu26Val), NCI-TCGA TCGA novel, REVEL 0.18, CADD 15.80, Variant assessed as somatic; moderate impact.
- W27R (p.Trp27Arg), Ensembl rs2147861444
- W27* (p.Trp27Ter), gnomAD X-71147830-G-A, CADD 34.00
- F28F (p.Phe28Phe), rs769129129, gnomAD X-71147833-C-T, CADD 10.60
- L29F (p.Leu29Phe), gnomAD rs1197857679, REVEL 0.09, CADD 20.40
- S30C (p.Ser30Cys), gnomAD X-71147837-A-T, REVEL 0.14, CADD 17.20
- L31F (p.Leu31Phe), rs1258826819, ClinGen CA413546945, ClinVar RCV003329889, ClinVar RCV005377355, REVEL 0.12, CADD 16.90, Uncertain significance, not provided; Inborn genetic diseases
- A32V (p.Ala32Val), rs1459104193, NCI-TCGA Cosmic COSV1007, cosmic curated COSV10070, gnomAD rs1459104193, REVEL 0.10, CADD 14.80, Variant assessed as somatic; moderate impact.
- A32A (p.Ala32Ala), rs774680366, gnomAD X-71147845-G-A, CADD 9.43
- L33L (p.Leu33Leu), gnomAD X-71147848-G-C, CADD 8.10
- R34K (p.Arg34Lys), Ensembl rs2147861503
- A35V (p.Ala35Val), NCI-TCGA TCGA novel, REVEL 0.10, CADD 15.10, Variant assessed as somatic; moderate impact.
- A35A (p.Ala35Ala), rs762316234, gnomAD X-71147854-C-T, CADD 10.90
- T37A (p.Thr37Ala), gnomAD X-71147858-A-G, REVEL 0.06, CADD 11.50
- Q38H (p.Gln38His), NCI-TCGA Cosmic COSV6244, cosmic curated COSV62442, Variant assessed as somatic; moderate impact.
- A39G (p.Ala39Gly), gnomAD X-71147865-C-G, REVEL 0.15, CADD 16.60
- A39A (p.Ala39Ala), gnomAD X-71147866-C-T, CADD 10.10
- P40A (p.Pro40Ala), TOPMed rs994006472, REVEL 0.10, CADD 11.00
- P40P (p.Pro40Pro), gnomAD X-71147869-A-C, CADD 8.26
- A41E (p.Ala41Glu), TOPMed rs1433975748, gnomAD rs1433975748, REVEL 0.11, CADD 17.20, Uncertain significance, Inborn genetic diseases
- A41T (p.Ala41Thr), NCI-TCGA Cosmic COSV6244, cosmic curated COSV62441, Variant assessed as somatic; moderate impact.
- A41A (p.Ala41Ala), gnomAD X-71147872-A-G, CADD 8.82
- T43S (p.Thr43Ser), gnomAD X-71147874-CCA-C, CADD 25.80
- T46I (p.Thr46Ile), gnomAD rs1371633897, REVEL 0.73, CADD 24.70
- F48S (p.Phe48Ser), Ensembl rs2092376469, REVEL 0.16, CADD 22.50
- G49E (p.Gly49Glu), rs2519735024, ClinGen CA413547184, ClinVar RCV003488148, Uncertain significance, not provided
- L51I (p.Leu51Ile), gnomAD rs1477798940, REVEL 0.18, CADD 15.30
- R52M (p.Arg52Met), NCI-TCGA Cosmic COSV6244, cosmic curated COSV62444, Variant assessed as somatic; moderate impact.
- R52S (p.Arg52Ser), cosmic curated COSV10650, Ensembl rs2147861588, REVEL 0.63, CADD 24.30
- G53D (p.Gly53Asp), ExAC rs776144240, gnomAD rs776144240
- A54T (p.Ala54Thr), rs1357228339, ClinGen CA413547239, ClinVar RCV003123233, TOPMed rs1357228339, AlphaMissense 0.07, MetaLR 0.05, Uncertain significance, not provided
- A54V (p.Ala54Val), gnomAD X-71147910-C-T, REVEL 0.14, CADD 16.20
- R55* (p.Arg55Ter), rs759137635, ClinGen CA10444973, ClinVar RCV003150609, ExAC rs759137635, AlphaMissense 0.71, MetaLR 0.42, Uncertain significance
- R55G (p.Arg55Gly), rs759137635, ClinGen CA413547254, ClinVar RCV001257609, ExAC rs759137635, AlphaMissense 0.71, MetaLR 0.42, Uncertain significance, Intellectual disability
- R55Q (p.Arg55Gln), rs764624943, NCI-TCGA Cosmic COSV6244, cosmic curated COSV62443, ExAC rs764624943, REVEL 0.47, CADD 24.20, Variant assessed as somatic; moderate impact.
- R55L (p.Arg55Leu), gnomAD X-71147913-G-T, REVEL 0.56, CADD 22.80
- V56E (p.Val56Glu), TOPMed rs2092376601
- V56I (p.Val56Ile), ExAC rs752463312, gnomAD rs752463312, REVEL 0.19, CADD 21.30
- P57L (p.Pro57Leu), rs757975693, ClinGen CA10444976, ClinVar RCV001354406, ClinVar RCV002548500, REVEL 0.41, CADD 22.60, Uncertain significance, Inborn genetic diseases
- P57S (p.Pro57Ser), NCI-TCGA Cosmic COSV6244, cosmic curated COSV62445, Variant assessed as somatic; moderate impact.
- L58L (p.Leu58Leu), gnomAD X-71147923-G-C, CADD 8.78
- P59S (p.Pro59Ser), gnomAD rs1386931400
- S60G (p.Ser60Gly), rs2092376672, ClinGen CA413547312, ClinVar RCV003229445, TOPMed rs2092376672, REVEL 0.20, CADD 22.00, Uncertain significance, not provided
- S60R (p.Ser60Arg), gnomAD X-71147929-T-G, REVEL 0.28, CADD 23.70
- L63P (p.Leu63Pro), NCI-TCGA Cosmic COSV6244, cosmic curated COSV62443, Variant assessed as somatic; moderate impact.
- L63V (p.Leu63Val), gnomAD X-71147936-C-G, REVEL 0.18, CADD 22.90
- L63L (p.Leu63Leu), rs763963502, gnomAD X-71147936-C-T, CADD 8.77
- G64R (p.Gly64Arg), TOPMed rs2092376734, cosmic curated COSV62444
- P65A (p.Pro65Ala), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- P65S (p.Pro65Ser), Ensembl rs978811511
- P65P (p.Pro65Pro), rs1031432721, gnomAD X-71147944-T-C, CADD 12.20
- V66V (p.Val66Val), rs1278819891, gnomAD X-71147947-G-A, CADD 9.97
- D67N (p.Asp67Asn), cosmic curated COSV10070, TOPMed rs1319874268, gnomAD rs1319874268
- D67Y (p.Asp67Tyr), TOPMed rs1319874268, gnomAD rs1319874268
- D67D (p.Asp67Asp), rs751334038, gnomAD X-71147950-C-T, CADD 10.00
- Q68E (p.Gln68Glu), gnomAD X-71147951-C-G, REVEL 0.50, CADD 24.00
- Y69Y (p.Tyr69Tyr), gnomAD X-71147956-C-T, CADD 8.54
- L70L (p.Leu70Leu), rs1181667526, gnomAD X-71147957-C-T, CADD 9.96
- G71G (p.Gly71Gly), gnomAD X-71147962-G-T, CADD 9.75
- V72C (p.Val72Cys), gnomAD X-71147958-TG-T, CADD 22.40
- P73S (p.Pro73Ser), NCI-TCGA Cosmic COSV6244, cosmic curated COSV62443, Variant assessed as somatic; moderate impact.
- P73T (p.Pro73Thr), gnomAD X-71147966-C-A, REVEL 0.93, CADD 24.50
- P73P (p.Pro73Pro), rs577101177, gnomAD X-71147968-C-G, CADD 10.80
- Y74* (p.Tyr74Ter), gnomAD X-71147971-C-A, CADD 28.20
- Y74Y (p.Tyr74Tyr), rs566418236, gnomAD X-71147971-C-T, CADD 5.66
- A75T (p.Ala75Thr), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- A75E (p.Ala75Glu), gnomAD X-71147973-C-A, REVEL 0.93, CADD 25.00
- A76T (p.Ala76Thr), rs2092376950, ClinGen CA413547568, ClinVar RCV002474215, TOPMed rs2092376950, REVEL 0.08, CADD 20.20, Uncertain significance, not provided
- A76D (p.Ala76Asp), gnomAD X-71147976-C-A, REVEL 0.28, CADD 23.20
- P77A (p.Pro77Ala), TOPMed rs1211820354, gnomAD rs1211820354, Uncertain significance
- P77S (p.Pro77Ser), rs1211820354, ClinGen CA413547595, cosmic curated COSV62444, ClinVar RCV002457536, REVEL 0.56, CADD 22.90, Uncertain significance, Inborn genetic diseases
- P78L (p.Pro78Leu), NCI-TCGA Cosmic COSV1007, NCI-TCGA Cosmic COSV6244, cosmic curated COSV62445, REVEL 0.92, CADD 25.30, Variant assessed as somatic; moderate impact.
- P78R (p.Pro78Arg), NCI-TCGA Cosmic COSV6244, Variant assessed as somatic; high impact.
- P78P (p.Pro78Pro), rs745776839, gnomAD X-71147983-G-C, CADD 1.89
- I79M (p.Ile79Met), rs756256945, ClinGen CA10444983, ClinVar RCV003489624, ExAC rs756256945, REVEL 0.27, CADD 21.50, Uncertain significance, not specified
- I79I (p.Ile79Ile), rs756256945, gnomAD X-71147986-C-T, CADD 9.04
- G80S (p.Gly80Ser), rs749579878, ExAC rs749579878, TOPMed rs749579878, gnomAD rs749579878, REVEL 0.86, CADD 26.40, Variant assessed as somatic; moderate impact.
- G80R (p.Gly80Arg), gnomAD X-71147987-G-C, REVEL 0.78, CADD 26.70
- G80G (p.Gly80Gly), rs766272859, gnomAD X-71147989-C-T, CADD 11.50
- E81D (p.Glu81Asp), ExAC rs748466850, TOPMed rs748466850, gnomAD rs748466850, REVEL 0.09, CADD 16.20
- E81K (p.Glu81Lys), rs768698460, ClinGen CA10444985, NCI-TCGA Cosmic COSV6244, cosmic curated COSV62444, REVEL 0.32, CADD 22.90, Uncertain significance, Inborn genetic diseases
- E81V (p.Glu81Val), ExAC rs774698648, gnomAD rs774698648, REVEL 0.53, CADD 22.90
- K82Q (p.Lys82Gln), rs2092377179, ClinGen CA413547707, ClinVar RCV001251852, Ensembl rs2092377179, AlphaMissense 0.25, MetaLR 0.25, Likely benign, Intellectual disability
- K82K (p.Lys82Lys), gnomAD X-71147995-A-G, CADD 12.00
- R83C (p.Arg83Cys), rs2147861944, ClinGen CA413547738, NCI-TCGA Cosmic COSV6244, cosmic curated COSV62441, AlphaMissense 0.99, MetaLR 0.84, Uncertain significance, not provided
- R83S (p.Arg83Ser), gnomAD X-71147996-C-A, REVEL 0.90, CADD 25.00
- F84F (p.Phe84Phe), gnomAD X-71148001-C-T, CADD 10.70
- L85V (p.Leu85Val), rs2519735445, ClinGen CA413547772, ClinVar RCV003893818, Uncertain significance, NLGN3-related disorder
- L85L (p.Leu85Leu), rs772407319, gnomAD X-71148004-G-A, CADD 9.96
- P86T (p.Pro86Thr), gnomAD X-71148005-C-A, REVEL 0.68, CADD 24.40
- P86S (p.Pro86Ser), gnomAD X-71148005-C-T, REVEL 0.53, CADD 24.60
- P86L (p.Pro86Leu), gnomAD X-71148006-C-T, REVEL 0.72, CADD 25.60
- P87L (p.Pro87Leu), gnomAD X-71148004-GC-G, CADD 26.60
- P89P (p.Pro89Pro), gnomAD X-71148016-A-C, CADD 11.20
- P90T (p.Pro90Thr), TOPMed rs1878234344
- P90L (p.Pro90Leu), gnomAD X-71148018-C-T, REVEL 0.43, CADD 25.60
- P90P (p.Pro90Pro), gnomAD X-71148019-C-G, CADD 11.10
- P91H (p.Pro91His), gnomAD X-71148016-AC-A, CADD 28.10
- P91P (p.Pro91Pro), gnomAD X-71148022-A-C, CADD 6.07
- S92Y (p.Ser92Tyr), rs17854698, UniProt VAR 068887, Ensembl rs17854698, AlphaMissense 0.31, MetaLR 0.54
- S92S (p.Ser92Ser), gnomAD X-71148025-C-T, CADD 10.10
- W93R (p.Trp93Arg), NCI-TCGA Cosmic COSV1007, cosmic curated COSV10070, Variant assessed as somatic; moderate impact.
- W93* (p.Trp93Ter), gnomAD X-71148028-G-A, CADD 36.00
- S94L (p.Ser94Leu), NCI-TCGA Cosmic COSV6244, cosmic curated COSV62442, TOPMed rs2092377244, REVEL 0.29, CADD 22.80, Variant assessed as somatic; moderate impact.
- S94S (p.Ser94Ser), rs143817848, gnomAD X-71148031-G-A, CADD 7.48
- G95A (p.Gly95Ala), Ensembl rs917449837, REVEL 0.62, AlphaMissense 0.30
- G95D (p.Gly95Asp), rs917449837, NCI-TCGA Cosmic COSV1007, cosmic curated COSV10070, Ensembl rs917449837, AlphaMissense 0.30, MetaLR 0.48, Variant assessed as somatic; moderate impact.
- R97W (p.Arg97Trp), rs761085827, ExAC rs761085827, gnomAD rs761085827, REVEL 0.62, CADD 27.20, Variant assessed as somatic; moderate impact.
- R97Q (p.Arg97Gln), gnomAD X-71148039-G-A, REVEL 0.48, CADD 27.20
- N98N (p.Asn98Asn), rs779027498, gnomAD X-71148043-C-T, CADD 12.30
- A99G (p.Ala99Gly), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- A99T (p.Ala99Thr), rs1342353331, NCI-TCGA Cosmic COSV6244, cosmic curated COSV62443, REVEL 0.65, CADD 23.80, Variant assessed as somatic; moderate impact.
- A99V (p.Ala99Val), NCI-TCGA Cosmic COSV1007, cosmic curated COSV10070, Variant assessed as somatic; moderate impact.
- A99A (p.Ala99Ala), gnomAD X-71148046-C-T, CADD 13.40
- T100K (p.Thr100Lys), gnomAD X-71148048-C-A, REVEL 0.83, CADD 25.90
- H101R (p.His101Arg), gnomAD X-71148051-A-G, REVEL 0.15, CADD 18.30
- F102L (p.Phe102Leu), Ensembl rs1602313559
- P103L (p.Pro103Leu), NCI-TCGA Cosmic COSV1007, cosmic curated COSV10070, Variant assessed as somatic; moderate impact.
- P103S (p.Pro103Ser), NCI-TCGA Cosmic COSV6244, cosmic curated COSV62444, Variant assessed as somatic; moderate impact.
- P103T (p.Pro103Thr), rs1288368410, ClinGen CA413548132, ClinVar RCV004493329, TOPMed rs1288368410, AlphaMissense 0.25, MetaLR 0.18, Uncertain significance, Inborn genetic diseases
- P104L (p.Pro104Leu), ExAC rs774807691, gnomAD rs774807691, REVEL 0.83, CADD 25.80
- P104R (p.Pro104Arg), ExAC rs774807691, gnomAD rs774807691, Uncertain significance, not provided
- C106Y (p.Cys106Tyr), NCI-TCGA Cosmic COSV1007, cosmic curated COSV10070, Variant assessed as somatic; moderate impact.
- C106C (p.Cys106Cys), gnomAD X-71148067-C-T, CADD 12.40
- Q108Q (p.Gln108Gln), rs2092377437, gnomAD X-71148073-G-A, CADD 11.50
- N109S (p.Asn109Ser), ExAC rs763800070, gnomAD rs763800070, REVEL 0.09, CADD 18.70
- N109N (p.Asn109Asn), rs751421871, gnomAD X-71148076-C-T, CADD 9.66
- H111R (p.His111Arg), NCI-TCGA Cosmic COSV1007, cosmic curated COSV10070, Variant assessed as somatic; moderate impact.
Public NLGN3 analysis runs
- NLGN3 analysis run — NLGN3 (749 variants) — completed 2026-08-19